Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Novello, 2016, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 27, v1, 10.1093/annonc/mdw326 Califano, 2016, Immune checkpoint blockade: a new era for non-small cell lung cancer, Curr Oncol Rep, 18, 59, 10.1007/s11912-016-0544-7 Marrone, 2016, Immune checkpoint therapy in non-small cell lung cancer, Cancer J, 22, 81, 10.1097/PPO.0000000000000178 Kawaguchi, 2014, Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA), J Clin Oncol, 32, 1902, 10.1200/JCO.2013.52.4694 Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Abdel-Rahman, 2016, Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis, Crit Rev Oncol Hematol, 101, 75, 10.1016/j.critrevonc.2016.03.007 Zhou, 2016, Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: a meta-analysis of randomized clinical trials, Medicine (Baltimore), 95, e4611, 10.1097/MD.0000000000004611 Bylicki, 2017, Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer, Target Oncol, 12, 563, 10.1007/s11523-017-0510-9 Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin Cancer Res, 22, 4585, 10.1158/1078-0432.CCR-15-3101 Oganesyan, 2008, Structural characterization of a human Fc fragment engineered for lack of effector functions, Acta Crystallogr D Biol Crystallogr, 64, 700, 10.1107/S0907444908007877 Stewart, 2015, Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody, Cancer Immunol Res, 3, 1052, 10.1158/2326-6066.CIR-14-0191 Segal, 2014, A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data, Ann Oncol, 25, 1058PD Antonia, 2016, Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC), Ann Oncol, 27, 1216PD Rebelatto, 2016, Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma, Diagn Pathol, 11, 95, 10.1186/s13000-016-0545-8 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Brahmer, 2014, Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC, J Clin Oncol, 32, 8021, 10.1200/jco.2014.32.15_suppl.8021 Zhang, 2016, The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis, Oncotarget, 7, 78985, 10.18632/oncotarget.12587 Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, 16, 257, 10.1016/S1470-2045(15)70054-9 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Leighl, 2012, Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line, Curr Oncol, 19, S52, 10.3747/co.19.1114 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 Lee, 2017, Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis, J Thorac Oncol, 12, 403, 10.1016/j.jtho.2016.10.007 Spigel, 2016, Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies, Proc Am Soc Clin Oncol, 34, 9017, 10.1200/JCO.2016.34.15_suppl.9017